<DOC>
	<DOCNO>NCT00176020</DOCNO>
	<brief_summary>The study double-blind , randomize , placebo-controlled , single-center , 2 treatment , 3-­way crossover . Subjects randomly allocate treatment sequence – AAB , ABA BAA . The two treatment : - Treatment A : 500 mg nicotinic acid ( Niacor ( R ) ) - Treatment B : Niacor ( R ) Placebo Each trial period last one day , wash-out period least 2 day trial period . Five seven day study day 1 trial period 3 final safety examination .</brief_summary>
	<brief_title>Nicotinic Acid - Pharmacokinetics , Pharmacodynamics , Receptor Expression</brief_title>
	<detailed_description />
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Good state health physically mentally Treatment investigational product last 60 day day randomization study Regular use medication last 60 day day randomization study except oral contraceptive female participant Treatment 60 day day randomization study drug know welldefined potential toxicity major organ , substance know induce inhibit hepatic drug metabolism ( include general anesthetic ) Any drug intake ( include overthecounter remedy ) 2 week day randomization study , unless investigator considers drug intake clinically irrelevant purpose study Any acute chronic illness clinically relevant finding prestudy examination Presence , history sequelae gastrointestinal ( e.g . peptic ulcer ) , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug History hypersensitivity investigational product History presence abnormality vascular bed History presence dermatologic disease skin lesion , particular area choose flush measurement History allergy hypersensitivity drug food constituent History allergic diseases hypersensitivity , unless investigator considers clinically irrelevant purpose study Blood donation &gt; 400 ml 60 day day randomization study Smoking Positive result urine screen drug abuse alcohol breath test Known suspect drugdependent , include consumption &gt; 30 g alcohol per day Pregnancy lactation Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol Mental condition render subject unable understand nature , scope , possible consequence study Subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>nicotinic acid</keyword>
	<keyword>flush symptom</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>